patients

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing…

6 months ago

The Dermatology Group of Arkansas Welcomes Double Board-Certified Dermatologist to Practice

LITTLE ROCK, Ark., July 04, 2025 (GLOBE NEWSWIRE) -- The Dermatology Group of Arkansas are thrilled to welcome their newest,…

6 months ago

MEI Micro partners with Steadman Philippon Research Institute in new technology development

SANTA BARBARA, Calif., June 26, 2025 /PRNewswire/ -- MEI Micro, Inc. is partnering with Steadman Philippon Research Institute (SPRI) to develop…

6 months ago

‘Haven of Hope’ – Shelter Home for Underprivileged Cancer Patients Inaugurated in Kochi

The 'Haven of Hope' building, built under South Indian Bank's CSR initiative for underprivileged cancer patients, is now operational.A new…

6 months ago

Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team

Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team Egham, UK – 03 July 2025…

6 months ago

ReCerf Receives its CE Mark, Advancing Access to Ceramic Hip Resurfacing Across Europe

LEATHERHEAD, England, July 3, 2025 /PRNewswire/ -- MatOrtho® is proud to announce that the ReCerf® Hip Resurfacing Arthroplasty (HRA) has…

6 months ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of…

7 months ago

Draig Therapeutics Launches with $140 Million (107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders

Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric disorders with a rich pipeline of novel, potentially…

7 months ago

AVEROA receives European marketing authorization for XOANACYL, an Oral Therapy for Chronic Kidney Disease (CKD)

XOANACYL is an oral therapy designed to address critical challenges in CKD, including Iron deficiency and hyperphosphatemia Averoa submitted XOANACYL…

7 months ago

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever…

7 months ago